In the history of LDL cholesterol inherited Hypercholeresterolemia has always been an important topic. Despite of modern innovative lipid lowering drugs around 805 of patients do not reach the target values. This new edition of Kirchheim library portraits Alirocumab, an new active ingredient to treat PCSK9.
In the history of LDL cholesterol inherited Hypercholeresterolemia has always been an important topic. Despite of modern innovative lipid lowering drugs around 805 of patients do not reach the target values. This new edition of Kirchheim library portraits Alirocumab, an new active ingredient to treat PCSK9.
